Early CBD player sees sales rise more than 30%

By Hank Schultz contact

- Last updated on GMT

Getty Images
Getty Images
Medical Marijuana Inc, despite its name one of the early players in the hemp/CBD supplement field, has announced sales increases topping 30% and a move to develop products based on additional cannabinoids.

In its most recent earnings statement, the company reported $20.7 million in revenue for the second quarter of 2019, a 30.8% increase from the same period a year previously.  Most of the sales of the company’s consumer products were made through its network marketing subsidiary Kannaway. 

MLM division

Kannaway made its initial appearance this year on Direct Selling News​’ Global 100 list of the biggest MLMs.  Kannaway was listed in a tie for 100th place with a projected $60 million in annual revenue over the previous 12 months.  DSN​ published its most recent list in April.

Like many other companies in the direct selling space, MMI reported high margins on its products, topping 70%. But also like other MLMs, sales and marketing expenses were high too, topping 50%, driven mostly by commissions paid to sales associates.

New manufacturing capacity in Utah

In an earnings call with analysts, MMI also detailed work it has done to secure its supply chain by bringing more manufacturing capability in house.

“We find the strengthened Medical Marijuana Inc.’s vertical integration efforts and ownership of our supply chain, by adding a greater level of processing and refinement at our newly expanded warehouse and manufacturing facilities in Utah. We are investing in engineering and equipment that will allow us to control various sites of production of our products that we could not previously, while enabling us to further innovate our product lines,”​ said chief operating officer Blake Schroeder.  A transcript of the call has been posted on the site seekingalpha.com​.

For the full year, the company said revenue will approach $85 million.

CBG development effort

Stuart Titus, CEO of MMI, said the company is sitting pat on CBD.  There are many cannabinoids within the plant yet to explore, he said.

“In addition to our decade worth of research and development into the potential wellness benefits of CBD, one of the Medical Marijuana Inc. major investment companies AXIM Biotech has been researching and developing several cannabigerol, CBG products,” ​he said.

“CBG like CBD is a non-psychoactive cannabinoid. It is basically the stem cell cannabinoid the first cannabinoid that the cannabis plant develops. And certainly there are tremendous potential pharmaceutical allocations that’s an anti-inflammatory, a potential T-cell mediator and potential benefits for digestive disturbances,”​ Titus added.

Related news

Show more

Related products

show more

SR CarnoSyn® Benefits the Body

SR CarnoSyn® Benefits the Body

SR CarnoSyn® | 18-Oct-2021 | Product Presentation

SR CarnoSyn® is a game changer when it comes to everyday wellness and healthy aging and is now available in tablet form as part of a turnkey, private-label...

Welcome to Blue California Specialty Ingredients

Welcome to Blue California Specialty Ingredients

Blue California | 11-Oct-2021 | Product Presentation

At Blue California, our mission is to produce innovative and sustainable, custom ingredient solutions that are not just unique, they are also inspirational...

Botanical extracts from the Mediterranean rim

Botanical extracts from the Mediterranean rim

Robertet Health & Beauty | 08-Oct-2021 | Product Brochure

The Mediterranean rim is one of earth’s most biologically rich terrestrial regions. It induces a special flora, with arborescent crops and evergreen trees...

Glutathione - Essential for Cellular Integrity

Glutathione - Essential for Cellular Integrity

Kyowa Hakko | 05-Oct-2021 | Insight Guide

When talking about full-body wellness, it is important to remember that good health starts at the cellular level. A critical nutrient known to support...

Related suppliers

Follow us

Products

View more

Webinars